ASK1 (Phospho-Ser83) ELISA Kit

Name: ASK1 (Phospho-Ser83) ELISA Kit
SKU: DEIA-XYA235
Rating: 5 (1 reviews)

Regulatory status: For research use only, not for use in diagnostic procedures.

COA

SDS

Datasheet

Summary

Sample

cultured cells

Species Reactivity

Human

Detection Method

Indirect ELISA

Intended Use

The ASK1 (Phospho-Ser83) Cell-Based ELISA Kit is a convenient, lysate-free, high throughput and sensitive assay kit that can monitor ASK1 protein phosphorylation and expression profile in cells. The kit can be used for measuring the relative amounts of phosphorylated ASK1 in cultured cells as well as screening for the effects that various treatments, inhibitors (ie. siRNA or chemicals), or activators have on ASK1 phosphorylatio

Contents of Kit

1. 96-Well Cell Culture Clear-Bottom Microplate: 2 plates
2. 10x TBS: 24 mL (10x)
3. Quenching Buffer: 24 mL (1x)
4. Blocking Buffer: 50 mL (1x)
5. 10x Wash Buffer: 50 mL (10x)
6. 100x Anti-ASK1 (Phospho-Ser83) Antibody (Rabbit Polyclonal): 60 μL (100x), Red
7. 100x Anti-ASK1 Antibody (Rabbit Polyclonal): 60 μL (100x), Purple
8. 100x Anti-GAPDH Antibody (Mouse Monoclonal): 60 μL (100x), Green
9. HRP-Conjugated Anti-Rabbit IgG Antibody: 12 mL (1x), Glass
10. HRP-Conjugated Anti-Mouse IgG Antibody: 12 mL (1x), Glass
11. Primary Antibody Diluent: 12 mL (1x)
12. Ready-to-Use Substrate: 12 mL (1x), Brown
13. Stop Solution: 12 mL (1x)
14. Crystal Violet Solution: 12 mL (1x), Glass
15. SDS Solution: 24 mL (1x)
16. Adhesive Plate Seals: 4 seals

Storage

4°C/6 Months

Citations

Have you cited DEIA-XYA235 in a publication? Let us know and earn a reward for your research.

Documents

pdf COA

pdf SDS

pdf Datasheet

QA & Reviews

Customer Reviews

References

Identification of a novel microRNA profile including miR-106b, miR-17, miR-20b, miR-18a and miR-93 in the metastasis of nasopharyngeal carcinoma

CANCER BIOMARKERS

Authors: Zhou, Wei; Chang, Aoshuang; Zhao, Houyu; Ye, Huiping; Li, Dairong; Zhuo, Xianlu

Abstract

BACKGROUND: Metastasis often leads to poor prognosis in nasopharyngeal carcinoma (NPC) patients. Evidence has indicated the important roles of microRNA (miRNA) in cancer metastasis. The aim of this study was to identify and verify the key miRNAs that might be involved in the development of NPC metastasis. METHODS: Microarray data were obtained and analyzed to screen the differentially expressed miRNAs (DEMs) between NPC tissues with metastasis and those without metastasis. The target genes of the DEMs were predicted and their functions were annotated. Then, candidate hub genes were screened out through protein-protein interaction analysis, and the key miRNAs were identified. Afterwards, the expression levels of the key miRNAs were assessed by qRT-PCR based on an in vitro model. RESULTS: A total of 22 DEMs were screened out, and 616 target genes were predicted. Gene Ontology (GO) and pathway enrichment analysis showed that the target genes may be enriched in a diversity of GO terms and signaling pathways. Among them, eleven hub genes were identified, such as PTEN, KAT2B, CCND1, STAT3, and MAP3K5. Moreover, a five-miRNA profile (miR-106b, miR-17, miR-20b, miR-18a and miR-93) was identified and their expression levels were tested to be up-regulated in high-metastatic NPC cells relative to low-metastatic ones. CONCLUSION: The present study revealed that five miRNAs (miR-106b, miR-17, miR-20b, miR-18a and miR-93) and several hub genes such as PTEN, KAT2B, CCND1, STAT3, and MAP3K5, might play critical roles in the development of NPC metastasis. Future investigations are needed to confirm the results.

MiR-425 expression profiling in acute myeloid leukemia might guide the treatment choice between allogeneic transplantation and chemotherapy

JOURNAL OF TRANSLATIONAL MEDICINE

Authors: Yang, Chen; Shao, Tingting; Zhang, Huihui; Zhang, Ninghan; Shi, Xiaoying; Liu, Xuejiao; Yao, Yao; Xu, Linyan; Zhu, Shengyun; Cao, Jiang; Cheng, Hai; Yan, Zhiling; Li, Zhenyu; Niu, Mingshan; Xu, Kailin

Abstract

Background: Acute myeloid leukemia (AML) is a highly heterogeneous disease. MicroRNAs function as important biomarkers in the clinical prognosis of AML. Methods: This study identified miR-425 as a prognostic factor in AML by screening the TCGA dataset. A total of 162 patients with AML were enrolled for the study and divided into chemotherapy and allogeneic hematopoietic stem cell transplantation (allo-HSCT) groups. Results: In the chemotherapy group, patients with high miR-425 expression had significantly longer overall survival (OS) and event-free survival (EFS) compared with patients with low miR-425 expression. In multivariate analyses, high miR-425 expression remained independently predictive of a better OS (HR = 0.502, P = 0.005) and EFS (HR = 0.432, P = 0.001) compared with patients with low miR-425 expression. Then, all patients were divided into two groups based on the median expression levels of miR-425. Notably, the patients undergoing allo-HSCT had significantly better OS (HR = 0.302, P < 0.0001) and EFS (HR = 0.379, P < 0.0001) compared with patients treated with chemotherapy in the low-miR-425-expression group. Mechanistically, high miR-425 expression levels were associated with a profile significantly involved in regulating cellular metabolism. Among these genes, MAP3K5, SMAD2, and SMAD5 were predicted targets of miR-425. Conclusions: The expression of miR-425 may be useful in identifying patients in need of strategies to select the optimal therapy between chemotherapy and allo-HSCT treatment regimens. Patients with low miR-425 expression may consider early allo-HSCT.